Kenny Walter

Avapritinib represents the first ever treatment for a rare mutation for patients with gastrointestinal stromal tumors.

New research emphasizes importance of sleep in decreasing the odds of developing Alzheimer disease.

In a new study, investigators found that 40 mg and 60 mg lumateperone is clinically safe to treat schizophrenia.

A panel that includes patients, clinicians, and methodologists create a new set of recommendations for treating gastrointestinal bleeding prophylaxis.

Investigators examine new data exploring the link between antipsychotic use and negative outcomes for hospitalized adults.

Investigators look at persistent symptoms for GERD patients taking proton pump inhibitors.

Northwell Health will focus on 2 different clinical strategies for monitoring and treating severe traumatic brain injuries.

A specific allele could help predict whether a patient will develop anti-drug antibodies to infliximab and adalimumab for patients with Crohn’s disease.

Investigators test a new drug for geriatric patients with insomnia disorder.

In a new study, a team of investigators use new imaging techniques to accurately predict brain tissue damage for patients with Alzheimer disease.

In a new study, investigators link sleep duration for adolescents between 6-12 with developing psychiatric disorders 2 years later.

With a shortage of hearts available, investigators turn to HCV-positive donors to try to reduce wait times.

Having a dog or cat in the first 12 years of a child's life could reduce the risk of serious psychiatric disorders later on.

The new topical lotion is aimed at treating patients at least 9 years old with acne vulgaris.

In a new study, investigators examine whether a low FODMAP diet could be beneficial for patients suffering from quiescent IBD.

Investigators examine the exposure and overdose rates of a popular anxiety treatment for adolescents between 2000-2015.

Investigators decipher the differences along racial lines for cerebrospinal fluid amyloid, tau biomarkers and associated cutoffs for patients with mild cognitive impairment.

Without an FDA approved drug in the last decade, investigators have found ways to improve diagnostics for patients suffering from Alzheimer disease.

The ID-Cap System represents the only ingestible event marker able to transmit digital data within the body to an external receiver without direct skin contact.

Arjun Masurkar, MD, PhD, discusses some of the issues with Alzheimer disease clinical trials.

Arjun Masurkar, MD, PhD, discusses how genetic testing could usher in a new wave of diagnostics for Alzheimer disease.

In a new study, investigators suggest coffee may be used in prevention strategies for chronic kidney disease.

Investigators show how sleep deprivation has a cognitive impact the following day.

In a comparison, investigators find that surgery is more successful in treating GERD patients who do not respond to protein pump inhibitors.

In a 3-patient study presented at ASH, investigators believe they have found a therapeutic target to cure sickle cell disease.

In a study presented at the annual ASH meeting, investigators link biomarkers of cardiopulmonary, renal, and liver dysfunction with specific outcomes for adult sickle cell disease patients.

In the last decade, investigators have put an emphasis on better disease monitoring for digestive diseases. The result has been better patient outcomes.

During the annual ASH meeting, investigators present phase 1 data from a new dose-climbing trial.

Investigators point out some of the reasons as to why there are less African Americans involved in AML clinical trials.

During the annual ASH meeting, investigators issue new clinical development guidelines for sickle cell disease therapies.